{"id":"NCT03968978","sponsor":"AstraZeneca","briefTitle":"Tezepelumab Home Use Study","officialTitle":"A Multicenter, Randomized, Open-label, Parallel Group, Functionality, and Performance Study of an Accessorized Pre-filled Syringe and Autoinjector With Home-administered Subcutaneous Tezepelumab in Adolescent and Adult Subjects With Severe Asthma (PATH-HOME)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-05-21","primaryCompletion":"2020-06-05","completion":"2020-06-05","firstPosted":"2019-05-30","resultsPosted":"2021-07-29","lastUpdate":"2021-07-29"},"enrollment":216,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"BIOLOGICAL","name":"Tezepelumab (APFS)","otherNames":[]},{"type":"BIOLOGICAL","name":"Tezepelumab (AI)","otherNames":[]}],"arms":[{"label":"Tezepelumab (AI)","type":"EXPERIMENTAL"},{"label":"Tezepelumab (APFS)","type":"EXPERIMENTAL"}],"summary":"This is a multicenter, randomized, open-label, parallel-group study designed to assess healthcare provider and subject/caregiver reported functionality and performance of a single-use accessorized pre-filled syringe (APFS) or autoinjector (AI) with a fixed 210 mg dose of tezepelumab administered subcutaneously in the clinic and in an at-home setting.","primaryOutcome":{"measure":"Proportions of HCPs and Subjects/Caregivers Who Successfully Administered Tezepelumab in Clinic or at Home by Device Type","timeFrame":"Week 0, Week 4, Week 8, Week 12, Week 16, Week 20","effectByArm":[{"arm":"Teze 210 mg Q4W Via APFS","deltaMin":109,"sd":null},{"arm":"Teze 210 mg Q4W Via AI","deltaMin":105,"sd":null}],"pValues":[{"comp":"OG000","p":null},{"comp":"OG000","p":null},{"comp":"OG000","p":null},{"comp":"OG000","p":null},{"comp":"OG000","p":null},{"comp":"OG000","p":null},{"comp":"OG001","p":null},{"comp":"OG001","p":null},{"comp":"OG001","p":null},{"comp":"OG001","p":null},{"comp":"OG001","p":null},{"comp":"OG001","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":36,"countries":["United States","Canada","Japan","Poland"]},"refs":{"pmids":["33907423"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00011&amp;attachmentIdentifier=34dcbdad-0c68-4350-8ed5-7194d8bb9c97&amp;fileName=D5180C00011-sap-ed-2_(03-Sep-2020)-redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00011&amp;attachmentIdentifier=35e421e0-5181-469c-a1b9-577eb9e0d37b&amp;fileName=D5180C00011-csp-v2_-_CI_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":111},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Asthma","Pharyngitis"]}}